Clinical Characteristics of Neovascular Age-Related Macular Degeneration without Typical Drusen

Table 2

Results of anti-VEGF therapy in nAMD with and without drusen.

	AMD with drusen (n = 52)	AMD without drusen (n = 81)
Baseline, mean (SD)
VA (logMAR)	0.41 (0.51)	0.30 (0.27)	0.80
CRT (μm)	317.3 (114.8)	340.1 (178.7)	0.65
SFCT (μm)	207.9 (99.5)	260.1 (113.2)	0.007
Outcome, mean (SD)
VA (logMAR)	0.52 (0.67)	0.36 (0.44)	0.28
CRT (μm)	226.9 (70.8)	239.3 (121.9)	0.91
SFCT (μm)	161.3 (85.7)	207.7 (97.9)	0.003
Change, mean (SD)
VA (logMAR)	0.12 (0.64)	0.05 (0.45)	0.69
CRT (μm)	90.5 (111.7)	100.8 (212.9)	0.98
SFCT (μm)	42.6 (71.0)	49.7 (68.2)	0.54
Follow-up (yrs), mean (SD)	5.0 (2.4)	4.9 (2.6)	0.76
Number of injections (no./yr), mean (SD)	4.7 (3.1)	4.6 (3.0)	0.78
RPE tear, number (%)	2 (3.8)	2 (2.5)	0.65
Subretinal hemorrhage, number (%)	3 (5.8)	6 (7.4)	0.71